▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / ISCO

ISCO — International Stem Cell CORP

—
OTC · Health Care · Pharmaceuticals · CIK 1355790 ·
Last close
$0.50
Market Cap
$3.99M
52W High
$0.54
52W Low
$0.16
ADV30
23,300
Next earnings
—
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It serves professional and retail customers. The company was founded in 2001 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,315,000 1,361,000 -190,000 -220,000 5,133,000 933,000 9,349,000
Dec 2025 2,155,000 1,089,000 -313,000 -348,000 4,819,000 993,000 8,879,000
Sep 2025 2,369,000 1,321,000 94,000 57,000 5,282,000 966,000 9,058,000
Jun 2025 2,447,000 1,520,000 167,000 129,000 5,547,000 920,000 9,443,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-98,000
Investing CF
$-71,000
Financing CF
$-150,000
CapEx
$-71,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.05
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-111,323,000
Inventory
$1,773,000
Receivables
$843,000
ST Investments
—
EBIT TTM
$-237,000
Pretax Income TTM
$-382,000
Interest Exp TTM
$145,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,514,000
EBITDA
$-162,000
Free Cash Flow
$394,750
Enterprise Value
$10,657,186
Total Cash
$1,089,000
Total Debt
$3,455,000
Shares Out
8,004,389
Trailing EPS
$-0.07
Book Value
$-0.53
ROE
-244.5%
ROA
-3.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 9,100,000 -267,000 -418,000 4,819,000 8,879,000 — 8,000
Dec 2024 9,085,000 -68,000 -209,000 5,173,000 9,103,000 — 13,000
Dec 2023 7,789,000 -663,000 -131,000 5,390,000 9,577,000 — 929,000
Dec 2022 8,180,000 -183,000 -331,000 5,135,000 9,655,000 — 332,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88

Peers — same industry

TickerNameMarket CapLastDaily %
GRI GRI Bio, Inc. $3.91M $1.79 —
SILO Silo Pharma, Inc. $4.10M $2.58 —
CVSI CV Sciences, Inc. $4.16M $0.02 —
SPRC SciSparc Ltd. $3.82M $6.66 —
SXTP 60 DEGREES PHARMACEUTICALS, INC. $3.80M $1.08 —

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →